Overview
News Overview
May 16, 2008
Phase III Asia-Pacific Study:
Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent
Trial Results Confirm Efficacy for Population Most Affected by the Disease » more
1:36 min.
Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent
Trial Results Confirm Efficacy for Population Most Affected by the Disease » more
1:36 min.May 15, 2008
Bayer to Help Victims of Natural Disasters in China and Burma
Goods and Funds Donation in the Amount of 350,000 Euros » more
1:12 min.
Goods and Funds Donation in the Amount of 350,000 Euros » more
1:12 min.May 13, 2008
First realization of a new climate concept for commercial buildings
Bayer lays the foundation for its zero-emission building in India
The “EcoCommercial Building” concept saves 70 percent of electrical energy / Chairman of the Bayer Board of Management Werner Wenning: “A milestone in the Bayer Climate Program” / More buildings to follow in other climate zones » more
1:17 min.
Bayer lays the foundation for its zero-emission building in India
The “EcoCommercial Building” concept saves 70 percent of electrical energy / Chairman of the Bayer Board of Management Werner Wenning: “A milestone in the Bayer Climate Program” / More buildings to follow in other climate zones » more
1:17 min.May 8, 2008
Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
International study to evaluate efficacy and safety in treating a leading cause of blindness » more
1:20 min.
International study to evaluate efficacy and safety in treating a leading cause of blindness » more
1:20 min.May 6, 2008
April 25, 2008
Werner Wenning at the Bayer AG Annual Stockholders’ Meeting
“2007 was Bayer’s most successful year to date”
Previous year’s record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded » more
1:32 min.
“2007 was Bayer’s most successful year to date”
Previous year’s record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded » more
5:33 min. 1:32 min.April 24, 2008
Interim report for the first quarter of 2008
Bayer off to an excellent start in 2008
Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for CropScience raised / Positive Group forecast confirmed » more
Bayer off to an excellent start in 2008
Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for CropScience raised / Positive Group forecast confirmed » more
April 17, 2008
World Hemophilia Day on April 17th
Bayer donates €250,000 for patients with hemophilia and provides nearly 1 million international units of Kogenate®
» more
Bayer donates €250,000 for patients with hemophilia and provides nearly 1 million international units of Kogenate®
» more
April 2, 2008
Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical
Merger to Be Completed Shortly » more
Merger to Be Completed Shortly » more
March 31, 2008
Bayer appeals invalidity ruling on its Yasmin® Patent
Appeal will be heard by the Federal Circuit » more
Appeal will be heard by the Federal Circuit » more
March 20, 2008
March 11, 2008
Bayer HealthCare to acquire OTC Business of Sagmel, Inc.
Acquisition strengthens Bayer Consumer Care’s Presence in Eastern Europe » more
1:10 min.
Acquisition strengthens Bayer Consumer Care’s Presence in Eastern Europe » more
1:10 min.March 3, 2008
Court decides against Bayer’s Yasmin® patent
Bayer HealthCare margin target (EBITDA before special items) for 2008 slightly adjusted – margin target for 2009 remains unchanged / Company will consider its legal options » more
Bayer HealthCare margin target (EBITDA before special items) for 2008 slightly adjusted – margin target for 2009 remains unchanged / Company will consider its legal options » more
February 28, 2008
Spring Financial News Conference:
Wenning: 2007 was Bayer’s most successful year to date
Sales grew 11.8 percent to EUR 32,385 million / EBITDA before special items advanced 21.4 percent to EUR 6,777 million / Performance target for 2007 exceeded: underlying EBITDA margin of 20.9 percent / EBIT before special items climbed 23.2 percent to EUR 4,287 million / Group net income totaled EUR 4,711 million – boosted by divestiture proceeds / Further earnings increase expected for 2008 » more
1:20 min.
Wenning: 2007 was Bayer’s most successful year to date
Sales grew 11.8 percent to EUR 32,385 million / EBITDA before special items advanced 21.4 percent to EUR 6,777 million / Performance target for 2007 exceeded: underlying EBITDA margin of 20.9 percent / EBIT before special items climbed 23.2 percent to EUR 4,287 million / Group net income totaled EUR 4,711 million – boosted by divestiture proceeds / Further earnings increase expected for 2008 » more
1:20 min.February 26, 2008
February 20, 2008
February 18, 2008
February 11, 2008
January 28, 2008
Nexavar® Approved for the Treatment of Kidney Cancer in Japan
First approved oral targeted therapy for metastatic RCC in Japan » more
1:36 min.
First approved oral targeted therapy for metastatic RCC in Japan » more
1:36 min.
more News
Bookmark this page
E-mail this page
Order print version
